Nearly 12% of Americans Have Tried GLP-1 Based Weight Loss Medications

Nearly 12% of Americans have used GLP-1 medications like Ozempic for weight loss. The use is most common among women aged 50-64, with the drugs gaining popularity due to proven effectiveness and notable side effects such as nausea and diarrhea.
A recent study by RAND Corporation reveals that approximately 12% of the adult population in the United States has used GLP-1 receptor agonist drugs for weight reduction purposes. These medications, including well-known drugs like Ozempic, have gained popularity due to their significant role in facilitating weight loss, especially after numerous studies demonstrated their effectiveness. The survey examined a representative sample of 8,793 Americans, finding that about 11.8% have directly used these drugs, while another 14% expressed interest in trying them. Interestingly, usage rates vary across different demographics, with women aged 50 to 64 exhibiting the highest utilization. Among individuals aged 65 and above, the use was slightly higher in men, whereas women aged 30 to 49 were more than twice as likely to have taken these medications compared to their male counterparts.
The survey also highlighted common side effects experienced by users, predominantly nausea and diarrhea, affecting roughly half and one-third of the users, respectively. Since 2020, prescriptions for GLP-1 drugs have more than tripled, reflecting their rising prominence in weight management strategies. The increasing adoption of these drugs aligns with growing evidence of their efficacy in significant weight reduction, making them a cornerstone in contemporary obesity treatment.
Conducted during April and May of 2025, the study forms part of the largest and most recent research efforts to understand the extent of GLP-1 drug use in the U.S. This trend underscores a shift in weight loss approaches and highlights the importance of understanding both the benefits and side effects associated with these medications. The findings also point towards a demographic skew, with women in middle age leading the adoption of GLP-1 therapies.
Authors of the report include Robert Bozick, Shannon Donofry, and Katherine M. Rancaño, providing valuable insights into the evolving landscape of obesity treatment. This research emphasizes the growing influence of pharmacological solutions in weight management and the importance of monitoring side effects for safe use.
For further details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Why Everyone, Regardless of Skin Tone, Should Wear Sunscreen
Discover why wearing sunscreen is crucial for all skin tones to prevent skin damage, aging, and skin cancer. Learn the best practices for effective sun protection.
GSK Acquires Promising Liver Disease Medication in Deal Valued at Up to $2 Billion
GSK is investing up to $2 billion to acquire efimosfermin, a promising drug in late-stage trials for treating fatty liver disease, which could revolutionize care and lower healthcare costs. Source: medicalxpress.com
Empagliflozin Provides Kidney Protection and Heart Failure Risk Reduction in Acute Myocardial Infarction Patients
Empagliflozin shows promise in protecting kidney function and reducing heart failure risk in patients after acute myocardial infarction, according to recent research.
Ebola Vaccine Deployment at Congo Outbreak Epicenter Amid Containment Challenges
Urgent vaccination efforts are underway in Congo’s Kasai province to control the first Ebola outbreak in 18 years, amid logistical challenges and limited resources.